UNITED THERAPEUTICS Corp (UTHR) stock
UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3022% above fair value
$577.34−6.76 (-1.16%)
Close on Nov 18, 2026Market cap $24.76BP/E 20.7Yield –
United Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
United Therapeutics's operating income for the twelve months ending Jun 30, 2026 was $1.40B, down 3.2% year over year. For fiscal 2025 it was $1.49B, up 8.4% from the year before. Over ten years it grew 7.9% a year on average. The highest annual figure on record is $1.49B in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.49B | +8.4% |
| FY2024 | Dec 31, 2024 | $1.38B | +16.2% |
| FY2023 | Dec 31, 2023 | $1.18B | +20.9% |
| FY2022 | Dec 31, 2022 | $979.70M | +76.2% |
| FY2021 | Dec 31, 2021 | $555.90M | -6.4% |
| FY2020 | Dec 31, 2020 | $593.60M | – |
| FY2019 | Dec 31, 2019 | -$187.60M | -123.3% |
| FY2018 | Dec 31, 2018 | $805.40M | -1.2% |
| FY2017 | Dec 31, 2017 | $814.90M | -23.2% |
| FY2016 | Dec 31, 2016 | $1.06B | +51.9% |
| FY2015 | Dec 31, 2015 | $699.00M | +29.7% |
| FY2014 | Dec 31, 2014 | $538.80M | +84.2% |
| FY2013 | Dec 31, 2013 | $292.50M | -30.6% |
| FY2012 | Dec 31, 2012 | $421.65M | +32.7% |
| FY2011 | Dec 31, 2011 | $317.78M | +85.5% |
| FY2010 | Dec 31, 2010 | $171.31M | +565.1% |
| FY2009 | Dec 31, 2009 | $25.76M | – |
| FY2008 | Dec 31, 2008 | -$82.06M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $330.80M | -9.2% |
| Q1 FY2026 | Mar 31, 2026 | $325.80M | -14.9% |
| Q4 FY2025 | Dec 31, 2025 | $356.70M | -0.3% |
| Q3 FY2025 | Sep 30, 2025 | $388.50M | +13.2% |
| Q2 FY2025 | Jun 30, 2025 | $364.50M | +13.9% |
| Q1 FY2025 | Mar 31, 2025 | $382.80M | +7.4% |
| Q4 FY2024 | Dec 31, 2024 | $357.70M | +37.5% |
| Q3 FY2024 | Sep 30, 2024 | $343.10M | +4.9% |
| Q2 FY2024 | Jun 30, 2024 | $319.90M | +2.1% |
| Q1 FY2024 | Mar 31, 2024 | $356.30M | +25.3% |
| Q4 FY2023 | Dec 31, 2023 | $260.10M | +48.1% |
| Q3 FY2023 | Sep 30, 2023 | $327.00M | +4.0% |
| Q2 FY2023 | Jun 30, 2023 | $313.40M | +55.3% |
| Q1 FY2023 | Mar 31, 2023 | $284.40M | -1.2% |
| Q4 FY2022 | Dec 31, 2022 | $175.60M | +3.4% |
| Q3 FY2022 | Sep 30, 2022 | $314.30M | +37.4% |
| Q2 FY2022 | Jun 30, 2022 | $201.80M | -9.2% |
| Q1 FY2022 | Mar 31, 2022 | $288.00M | – |
| Q4 FY2021 | Dec 31, 2021 | $169.80M | +160.0% |
| Q3 FY2021 | Sep 30, 2021 | $228.70M | +3.4% |
| Q2 FY2021 | Jun 30, 2021 | $222.20M | +58.1% |
| Q1 FY2021 | Mar 31, 2021 | -$64.80M | -138.9% |
| Q4 FY2020 | Dec 31, 2020 | $65.30M | +2.8% |
| Q3 FY2020 | Sep 30, 2020 | $221.10M | +20.6% |
| Q2 FY2020 | Jun 30, 2020 | $140.50M | -36.5% |
| Q1 FY2020 | Mar 31, 2020 | $166.70M | – |
| Q4 FY2019 | Dec 31, 2019 | $63.50M | -51.7% |
| Q3 FY2019 | Sep 30, 2019 | $183.40M | +22.6% |
| Q2 FY2019 | Jun 30, 2019 | $221.40M | +1.8% |
| Q1 FY2019 | Mar 31, 2019 | -$655.90M | -313.7% |
| Q4 FY2018 | Dec 31, 2018 | $131.50M | -5.4% |
| Q3 FY2018 | Sep 30, 2018 | $149.60M | -53.8% |
| Q2 FY2018 | Jun 30, 2018 | $217.40M | +145.6% |
| Q1 FY2018 | Mar 31, 2018 | $306.90M | +16.4% |
| Q4 FY2017 | Dec 31, 2017 | $139.00M | -20.2% |
| Q3 FY2017 | Sep 30, 2017 | $323.80M | +35.7% |
| Q2 FY2017 | Jun 30, 2017 | $88.50M | – |
| Q1 FY2017 | Mar 31, 2017 | $263.60M | – |
| Q4 FY2016 | Dec 31, 2016 | $174.20M | – |
| Q3 FY2016 | Sep 30, 2016 | $238.60M | – |
See a number that looks wrong?